{"id":"https://openalex.org/W2560152574","doi":"https://doi.org/10.1182/blood.v124.21.4671.4671","title":"Phase 1b Study of Otlertuzumab (TRU-016), an Anti-CD37 ADAPTIRTM Protein, in Combination with Rituximab in Patients with Chronic Lymphocytic Leukemia (CLL)","display_name":"Phase 1b Study of Otlertuzumab (TRU-016), an Anti-CD37 ADAPTIRTM Protein, in Combination with Rituximab in Patients with Chronic Lymphocytic Leukemia (CLL)","publication_year":2014,"publication_date":"2014-12-06","ids":{"openalex":"https://openalex.org/W2560152574","doi":"https://doi.org/10.1182/blood.v124.21.4671.4671","mag":"2560152574"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v124.21.4671.4671","doi":"https://doi.org/10.1182/blood.v124.21.4671.4671","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v124.21.4671.4671","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5024389256","display_name":"Kami J. Maddocks","orcid":"https://orcid.org/0000-0001-8519-8404","observed_orcids":["https://orcid.org/0000-0001-8519-8404"]},"institutions":[{"id":"https://openalex.org/I52357470","display_name":"The Ohio State University","ror":"https://ror.org/00rs6vg23","country_code":"US","type":"education","lineage":["https://openalex.org/I52357470"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kami J. Maddocks","raw_affiliation_strings":["The Ohio State University, Columbus, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Ohio State University, Columbus, OH","institution_ids":["https://openalex.org/I52357470"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040412322","display_name":"John M. Pagel","orcid":"https://orcid.org/0000-0001-5745-8125","observed_orcids":["https://orcid.org/0000-0001-5745-8125","https://orcid.org/0000-0003-2875-4878"]},"institutions":[{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John Pagel","raw_affiliation_strings":["Fred Hutchinson Cancer Research Center, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fred Hutchinson Cancer Research Center, Seattle, WA","institution_ids":["https://openalex.org/I4210089486"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000921376","display_name":"John C. Byrd","orcid":"https://orcid.org/0000-0001-9830-0711","observed_orcids":["https://orcid.org/0000-0001-9830-0711"]},"institutions":[{"id":"https://openalex.org/I52357470","display_name":"The Ohio State University","ror":"https://ror.org/00rs6vg23","country_code":"US","type":"education","lineage":["https://openalex.org/I52357470"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John C. Byrd","raw_affiliation_strings":["The Ohio State University, Columbus, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Ohio State University, Columbus, OH","institution_ids":["https://openalex.org/I52357470"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078642863","display_name":"Scott C. Stromatt","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Scott Stromatt","raw_affiliation_strings":["Emergent Product Development Seattle, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Emergent Product Development Seattle, Seattle, WA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5059854479","display_name":"Farrukh Tauseef Awan","orcid":"https://orcid.org/0000-0003-1813-9812","observed_orcids":["https://orcid.org/0000-0003-1813-9812"]},"institutions":[{"id":"https://openalex.org/I52357470","display_name":"The Ohio State University","ror":"https://ror.org/00rs6vg23","country_code":"US","type":"education","lineage":["https://openalex.org/I52357470"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Farrukh Awan","raw_affiliation_strings":["The Ohio State University, Columbus, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Ohio State University, Columbus, OH","institution_ids":["https://openalex.org/I52357470"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.7817,"has_fulltext":false,"cited_by_count":5,"citation_normalized_percentile":{"value":0.72857445,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":94,"max":97},"biblio":{"volume":"124","issue":"21","first_page":"4671","last_page":"4671"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cd37","display_name":"CD37","score":0.9150000214576721},{"id":"https://openalex.org/keywords/rituximab","display_name":"rituximab","score":0.9210000038146973},{"id":"https://openalex.org/keywords/chronic-lymphocytic-leukemia","display_name":"chronic lymphocytic leukemia","score":0.9860000014305115},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.7279999852180481},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.6340000033378601},{"id":"https://openalex.org/keywords/relapsed-refractory-cll","display_name":"relapsed/refractory CLL","score":0.6800000071525574},{"id":"https://openalex.org/keywords/previously-untreated-cll","display_name":"previously untreated CLL","score":0.550000011920929},{"id":"https://openalex.org/keywords/b-cell-death","display_name":"B cell death","score":0.3109999895095825}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8133863806724548},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.7531620264053345},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.6248738169670105},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.6032643914222717},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.599863588809967},{"id":"https://openalex.org/C2779015954","wikidata":"https://www.wikidata.org/wiki/Q420164","display_name":"Alemtuzumab","level":3,"score":0.5510707497596741},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.44721531867980957},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.4157811999320984},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3903430700302124},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3429359197616577},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.3352745473384857},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.3089074492454529},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.20450782775878906},{"id":"https://openalex.org/C2911091166","wikidata":"https://www.wikidata.org/wiki/Q106419912","display_name":"Transplantation","level":2,"score":0.09146279096603394}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v124.21.4671.4671","doi":"https://doi.org/10.1182/blood.v124.21.4671.4671","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v124.21.4671.4671","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2980152759","https://openalex.org/W4240347407","https://openalex.org/W2303421618","https://openalex.org/W2228641001","https://openalex.org/W1965159977","https://openalex.org/W1991267180","https://openalex.org/W7100155974","https://openalex.org/W2029117730","https://openalex.org/W7100842301","https://openalex.org/W2556995775"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"CD37":[2],"is":[3,31,419,425,432,439,480,484,499,622],"a":[4,18,32,155],"tetraspanin":[5],"protein":[6,35,40],"expressed":[7],"on":[8,37,133,188,215,221,249],"the":[9,38,81,117,174,189,195,199,206,238,250,273,277,290,336,409,443,467],"surface":[10],"of":[11,21,50,58,62,85,146,299,312,334,338,350,458,510,590],"normal":[12],"and":[13,55,83,106,142,166,192,218,224,226,258,276,284,314,325,352,372,376,381,402,460,491,517,611],"transformed":[14],"B":[15],"cells":[16,52,64],"across":[17],"wide":[19],"range":[20],"maturational":[22],"stages":[23],"that":[24,43],"mediates":[25],"death":[26],"signaling":[27],"via":[28],"SHP1.":[29],"Otlertuzumab":[30],"CD37-specific":[33],"therapeutic":[34,515],"built":[36],"ADAPTIRTM(modular":[39],"technology)":[41],"platform":[42],"has":[44],"shown":[45,288],"significantly":[46],"greater":[47],"direct":[48],"killing":[49],"CLL":[51,63,98,267],"than":[53,65],"rituximab":[54,69,90,235,479],"higher":[56],"levels":[57],"Fc-mediated":[59],"cellular":[60],"cytotoxicity":[61],"either":[66],"alemtuzumab":[67],"or":[68,136],"in":[70,87,91,266,289,332,348,404,476,505,588,634,637],"pre-clinical":[71],"models.":[72],"This":[73,482],"phase":[74],"1b":[75],"trial":[76],"was":[77,163,202,244,254,270,330,341,629],"conducted":[78],"to":[79,305,310,317,320,453],"evaluate":[80],"safety":[82],"efficacy":[84,516],"otlertuzumab":[86,147,247,475,504],"combination":[88,477,506],"with":[89,93,100,474,478,503,507,600,607,613],"patients":[92,99,121,124,179,211,295,414,447,599,636],"CLL.":[94],"Methods:":[95],"Eligibility":[96],"included":[97,353],"adequate":[101],"organ":[102],"function,":[103],"ECOG":[104],"\u22642,":[105],"absolute":[107],"neutrophil":[108],"count":[109],"\u2265800/\u03bcL.":[110],"Three":[111],"cohorts":[112],"have":[113,448],"been":[114,449],"enrolled.":[115],"In":[116,173,205,232,442],"1st":[118,196],"cohort,":[119,176,208],"24":[120],"previously":[122,412,625],"untreated":[123,413],"who":[125,180],"were":[126,140,170,186],"considered":[127],"ineligible":[128],"for":[129,149,157,229,263,488,624],"standard":[130],"chemotherapy":[131],"based":[132],"age,":[134],"comorbidity":[135],"patient":[137,424],"preference":[138],"(naive)":[139],"enrolled":[141],"received":[143,182,212],"IV":[144],"infusion":[145,354,603],"weekly":[148],"two":[150],"28-day":[151],"cycles":[152,298],"then":[153,227,241],"once":[154],"month":[156],"4":[158,615],"months.":[159,231,441],"The":[160,470,486,496],"first":[161,200,239],"dose":[162,191,201,240],"10":[164,219],"mg/kg":[165,214,220,411,525,527,529],"all":[167,233,297],"subsequent":[168],"doses":[169],"20":[171,410],"mg/kg.":[172,204],"2nd":[175],"16":[177,209,440],"relapsed":[178],"had":[181],"1-3":[183],"prior":[184],"therapies":[185],"treated":[187,502,626],"same":[190,251],"schedule":[193],"as":[194,631],"cohort":[197,489,498],"except":[198,597],"6":[203,213],"3rd":[207],"naive":[210],"Day":[216],"1":[217,373,389,405,423,452,606],"Days":[222],"8":[223],"15":[225],"monthly":[228],"5":[230,454,612],"cohorts,":[234,446],"(375":[236],"mg/m2":[237],"500":[242],"mg/m2)":[243],"administered":[245],"after":[246,456],"by":[248],"schedule.":[252],"Safety":[253],"evaluated":[255],"using":[256,272],"CTCAE":[257,518],"IWCLL":[259,279,416],"2008":[260,278],"Grading":[261],"scale":[262],"Hematologic":[264],"Toxicity":[265],"Studies.":[268],"Response":[269],"determined":[271],"1996":[274],"NCI":[275,429],"Criteria.":[280],"Results:":[281],"Patient":[282],"characteristics":[283],"adverse":[285,345],"events":[286,346],"are":[287],"table.":[291],"All":[292],"but":[293,628],"9":[294],"completed":[296],"therapy:":[300],"3":[301,308,315,492],"discontinued":[302],"early":[303],"due":[304,309,316],"progressive":[306],"disease;":[307],"lack":[311],"response,":[313,324],"AEs":[318],"(reaction":[319],"allopurinol,":[321],"systemic":[322,398],"inflammatory":[323,399],"rash).":[326],"Grade":[327,582,601,608,614],"3/4":[328,583,602,609],"neutropenia":[329,366,616],"reported":[331],"9%":[333],"patients;":[335],"incidence":[337],"severe":[339],"infections":[340],"low":[342],"(9%).":[343],"Serious":[344,585],"occurred":[347],"61%":[349],"pts":[351],"related":[355,604],"reaction":[356],"(28":[357],"pts,":[358],"2":[359,445,490,598,635],"grade":[360,388,519,595],"3,":[361],"26":[362],"\u2264grade":[363],"2),":[364],"febrile":[365],"(4":[367],"patients),":[368,380],"infection":[369],"(2":[370,379],"pneumonia":[371],"each":[374],"sinusitis":[375],"diverticulitis),":[377],"pyrexia":[378],"deep":[382],"vein":[383],"thrombosis,":[384],"lymph":[385],"node":[386],"pain,":[387],"acute":[390],"coronary":[391],"syndrome,":[392,401],"atrial":[393],"fibrillation,":[394],"small":[395],"intestinal":[396],"obstruction,":[397],"response":[400,417,430,461,472],"hyperkalemia":[403],"pt":[406],"each.":[407],"For":[408],"(n=24)":[415],"rate":[418,431,473],"54%":[420],"(8%":[421],"CR);":[422],"not":[426],"yet":[427],"evaluable.":[428],"96%":[433],"(38%":[434],"CR).":[435],"Median":[436],"progression-free":[437],"survival":[438],"other":[444],"followed":[450],"from":[451],"months":[455],"end":[457],"treatment":[459],"results":[462,487],"will":[463,493],"be":[464,494],"presented":[465],"at":[466],"meeting.":[468],"Conclusions:":[469],"preliminary":[471],"promising.":[481],"study":[483],"ongoing.":[485],"updated.":[495],"fourth":[497],"currently":[500],"being":[501],"obinutuzumab":[508],"instead":[509],"rituximab.":[511],"Tablel":[512],"1Basic":[513],"characteristics,":[514],"III/IV":[520],"toxicity.":[521],"Baseline":[522],"Characteristics":[523],"NaiveRelapsed20":[524],"(n=24)10":[526],"(n=16)20":[528],"(n=16)Age,":[530],"median":[531,542],"(range)65":[532],"(27-85)62":[533],"(48-88)63(47-74)Male,":[534],"n":[535,548,554,559,564,569,575],"(%)13":[536,570],"(54)10":[537],"(63)9":[538],"(56)\u03922":[539],"Microglobulin,":[540],"mg/dL,":[541],"(range)3.5":[543],"(2-6)2.9":[544],"(1-6)4..0":[545],"(2-10)CIRS":[546],"\u22646,":[547],"(%)14":[549],"(58)10":[550],"(63)11":[551],"(69)Rai":[552],"III/IV,":[553],"(%)5":[555],"(21)5":[556],"(31)11":[557],"(69)del17p,":[558],"(%)2":[560],"(8)1":[561],"(6)5":[562],"(31)del11q,":[563],"(%)7":[565],"(29)2":[566],"(13)2":[567],"(13)del13q,":[568],"(54)5":[571],"(31)7":[572],"(44)Trisomy":[573],"12,":[574],"(%)9":[576],"(38)4":[577],"(25)0Adverse":[578],"Events,":[579],"%Any":[580],"Event10094100Any":[581],"Event462563Any":[584],"Event756338Nonhematologic":[586],"Events":[587],"\u226510%":[589],"patients*Infusion-related":[591],"reaction67*5619Any":[592],"infection583125Nausea331325Diarrhea331331Headache17625Hypertension171913*Cough13196Pyrexia131913MyelosuppressionNeutropenia*13019Thrombocytopenia000Anemia4019":[593],"*All":[594],"1/2":[596],"reaction,":[605],"hypertension,":[610],"Disclosures":[617],"Off":[618],"Label":[619],"Use:":[620],"Ibrutinib":[621],"approved":[623],"MCL":[627],"used":[630],"first-line":[632],"therapy":[633],"this":[638],"report..":[639],"Byrd:Emergent":[640],"Product":[641,646],"Development:":[642,647],"Research":[643,650,652],"Funding.":[644],"Stromatt:Emergent":[645],"Employment.":[648],"Awan:Lymphoma":[649],"Foundation:":[651],"Funding;":[653],"Boehringer":[654],"Ingelheim:":[655],"Consultancy.":[656]},"counts_by_year":[{"year":2017,"cited_by_count":3},{"year":2015,"cited_by_count":2}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-12-16T00:00:00"}